selected publications
- TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models. Molecular therapy. Oncology. 2024 Academic Article GET IT
- Augmenting CAR T Cell Functions with LIGHT. Cancer immunology research. 2024 Academic Article GET IT
- Developing a membrane-proximal CD33-targeting CAR T cell. Journal for immunotherapy of cancer. 2024 Academic Article GET IT
- Endogenous CD28 drives CAR T cell responses in multiple myeloma. 2024 GET IT
- Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. 2024 GET IT
- Author Correction: T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. 2024 GET IT
- CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nature medicine. 2023 Academic Article GET IT
-
IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models.
The Journal of clinical investigation.
2023
Academic Article
GET IT
Times cited: 49 - The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022. Journal of translational medicine. 2023 Academic Article GET IT
- MEETING HIGHLIGHTS: THE THIRD MARIE SKŁODOWSKA-CURIE SYMPOSIUM ON CANCER RESEARCH AND CARE AT ROSWELL PARK COMPREHENSIVE CANCER CENTER, BUFFALO, NY, SEPTEMBER 20-22, 2023. Wiadomosci lekarskie (Warsaw, Poland : 1960). 2023 Academic Article GET IT
- GPRC5D-Targeted CAR T Cells for Myeloma. Reply. The New England journal of medicine. 2022 Letter GET IT
- CAR T cell therapy: looking back and looking forward. Nature cancer. 2022 Academic Article GET IT
- Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. 2022 GET IT
-
GPRC5D-Targeted CAR T Cells for Myeloma.
The New England journal of medicine.
2022
Academic Article
GET IT
Times cited: 193 -
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.
Nature reviews. Clinical oncology.
2022
Review
GET IT
Times cited: 63 -
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Nature medicine.
2022
Academic Article
GET IT
Times cited: 142 -
Multipurposing CARs: Same engine, different vehicles.
Molecular therapy : the journal of the American Society of Gene Therapy.
2022
Review
GET IT
Times cited: 9 -
CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience.
Journal for immunotherapy of cancer.
2022
Academic Article
GET IT
Times cited: 26 - Engineering CAR-T cells to activate small-molecule drugs in situ. Nature chemical biology. 2021 Academic Article GET IT
-
Human cytomegalovirus expands a CD8+ T cell population with loss of BCL11B expression and gain of NK cell identity.
Science immunology.
2021
Academic Article
GET IT
Times cited: 32 -
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells.
Blood advances.
2021
Academic Article
GET IT
Times cited: 85 -
Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy.
Blood.
2021
Academic Article
GET IT
Times cited: 45 -
Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing.
Molecular therapy. Methods & clinical development.
2021
Academic Article
GET IT
Times cited: 20 -
Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.
Frontiers in immunology.
2021
Academic Article
GET IT
Times cited: 24 -
Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia.
Leukemia.
2021
Academic Article
GET IT
Times cited: 25 - Chimeric Antigen Receptor-Modified Immune Effector Cell Therapies: Learning From the Present; Charting a Path to the Future. Cancer journal (Sudbury, Mass.). 2021 Editorial Article GET IT
-
Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15th-16th February 2019, Doha, Qatar.
Frontiers in immunology.
2021
Conference Paper
GET IT
Times cited: 1 -
Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages.
Nature communications.
2020
Academic Article
GET IT
Times cited: 93 -
CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function.
Nature communications.
2020
Academic Article
GET IT
Times cited: 22 -
Frontiers in cancer immunotherapy-a symposium report.
Annals of the New York Academy of Sciences.
2020
Review
GET IT
Times cited: 31 -
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia.
Journal for immunotherapy of cancer.
2020
Academic Article
GET IT
Times cited: 6 -
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma.
Blood cancer discovery.
2020
Academic Article
GET IT
Times cited: 135 -
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.
Blood advances.
2020
Academic Article
GET IT
Times cited: 186 -
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery.
Cancers.
2020
Information Resource
GET IT
Times cited: 20 - CAR T Cells for Mantle Cell Lymphoma: Is it Time to Reshuffle the Deck?. Cancer cell. 2020 Comment GET IT
-
Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response.
Leukemia.
2020
Academic Article
GET IT
Times cited: 38 -
Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant.
Bone marrow transplantation.
2020
Academic Article
GET IT
Times cited: 11 -
Enhancing CAR T cell efficacy: the next step toward a clinical revolution?.
Expert review of hematology.
2020
Review
GET IT
Times cited: 9 -
Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells.
Cancer immunology research.
2020
Academic Article
GET IT
Times cited: 22 -
Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy.
Cancer immunology research.
2020
Academic Article
GET IT
Times cited: 19 -
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.
British journal of haematology.
2020
Academic Article
GET IT
Times cited: 53 -
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management.
Blood advances.
2020
Academic Article
GET IT
Times cited: 113 -
Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells.
Clinical nephrology.
2020
Academic Article
GET IT
Times cited: 15 -
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.
Blood.
2019
Academic Article
GET IT
Times cited: 199 -
Engineering strategies to overcome the current roadblocks in CAR T cell therapy.
Nature reviews. Clinical oncology.
2019
Review
GET IT
Times cited: 868 -
Application of CAR T cells for the treatment of solid tumors.
Progress in molecular biology and translational science.
2019
Review
GET IT
Times cited: 13 -
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.
Blood.
2019
Academic Article
GET IT
Times cited: 60 -
CAR T-cell therapy: Full speed ahead.
Hematological oncology.
2019
Review
GET IT
Times cited: 102 -
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
JCI insight.
2019
Academic Article
GET IT
Times cited: 80 -
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Science translational medicine.
2019
Academic Article
GET IT
Times cited: 258 -
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.
Cancer cell.
2019
Academic Article
GET IT
Times cited: 162 -
CARs of the future.
American journal of hematology.
2019
Review
GET IT
Times cited: 9 -
Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.
EBioMedicine.
2018
Academic Article
GET IT
Times cited: 48 -
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
Journal for immunotherapy of cancer.
2018
Review
GET IT
Times cited: 177 -
Dawn of Chimeric Antigen Receptor T Cell Therapy in Non-Hodgkin Lymphoma.
Advances in cell and gene therapy.
2018
Academic Article
GET IT
Times cited: 140 -
Tumors evading CARs-the chase is on.
Nature medicine.
2018
Comment
GET IT
Times cited: 27 -
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.
Molecular therapy. Methods & clinical development.
2018
Academic Article
GET IT
Times cited: 23 -
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.
Nature biotechnology.
2018
Academic Article
GET IT
Times cited: 585 -
Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2018
Academic Article
GET IT
Times cited: 207 -
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.
Molecular therapy : the journal of the American Society of Gene Therapy.
2018
Academic Article
GET IT
Times cited: 64 -
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
Cancer discovery.
2018
Academic Article
GET IT
Times cited: 638 -
CAR T cells, immunologic and cellular therapies in hematologic malignancies.
Best practice & research. Clinical haematology.
2018
Editorial Article
GET IT
Times cited: 1 -
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System.
Cell reports.
2018
Academic Article
GET IT
Times cited: 245 -
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.
Molecular therapy : the journal of the American Society of Gene Therapy.
2018
Academic Article
GET IT
Times cited: 79 -
Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2018
Information Resource
GET IT
Times cited: 63 -
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.
Blood advances.
2018
Academic Article
GET IT
Times cited: 119 -
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
The New England journal of medicine.
2018
Academic Article
GET IT
Times cited: 1947 -
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.
Cancer cell.
2017
Academic Article
GET IT
Times cited: 131 -
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?.
Leukemia & lymphoma.
2017
Information Resource
GET IT
Times cited: 46 -
Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma.
Journal of the National Comprehensive Cancer Network : JNCCN.
2017
Review
GET IT
Times cited: 16 -
Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.
Leukemia & lymphoma.
2017
Article
GET IT
Times cited: 6 -
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.
Scientific reports.
2017
Academic Article
GET IT
Times cited: 300 -
Development of CAR T cells designed to improve antitumor efficacy and safety.
Pharmacology & therapeutics.
2017
Review
GET IT
Times cited: 90 -
Adoptive T-Cell Therapy for Solid Tumors.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
2017
Academic Article
GET IT
Times cited: 75 -
Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.
Leukemia.
2016
Academic Article
GET IT
Times cited: 125 -
CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia.
Clinical advances in hematology & oncology : H&O.
2016
Review
GET IT
Times cited: 102 -
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.
Cell.
2016
Academic Article
GET IT
Times cited: 199 -
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
Cytotherapy.
2016
Information Resource
GET IT
Times cited: 80 -
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.
Blood.
2016
Information Resource
GET IT
Times cited: 322 -
Medical management of side effects related to CAR T cell therapy in hematologic malignancies.
Expert review of hematology.
2016
Editorial Article
GET IT
Times cited: 42 -
Toxicity and management in CAR T-cell therapy.
Molecular therapy oncolytics.
2016
Information Resource
GET IT
Times cited: 687 -
Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.
Biochemical Society transactions.
2016
Review
GET IT
Times cited: 170 -
Driving CAR T-cells forward.
Nature reviews. Clinical oncology.
2016
Review
GET IT
Times cited: 507 -
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
Nature reviews. Clinical oncology.
2016
Information Resource
GET IT
Times cited: 804 -
Are chimeric antigen receptor T cells ready for prime time?.
Clinical advances in hematology & oncology : H&O.
2016
Academic Article
GET IT
Times cited: 3 -
Overcoming Antigen Escape with CAR T-cell Therapy.
Cancer discovery.
2015
Comment
GET IT
Times cited: 71 -
Novel immunotherapies in lymphoid malignancies.
Nature reviews. Clinical oncology.
2015
Review
GET IT
Times cited: 213 -
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.
Journal of translational medicine.
2015
Academic Article
GET IT
Times cited: 227 - IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015 Academic Article GET IT
-
Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.
Molecular therapy : the journal of the American Society of Gene Therapy.
2015
Academic Article
GET IT
Times cited: 201 -
CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?.
Immunotherapy.
2015
Review
GET IT
Times cited: 32 -
CD19 CAR Therapy for Acute Lymphoblastic Leukemia.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
2015
Information Resource
GET IT
Times cited: 32 -
CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date.
Cancer journal (Sudbury, Mass.).
2015
Review
GET IT
Times cited: 27 -
The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies.
Gene therapy.
2014
Academic Article
GET IT
Times cited: 26 -
High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.
Blood.
2014
Academic Article
GET IT
Times cited: 91 -
T-cell immunotherapy: looking forward.
Molecular therapy : the journal of the American Society of Gene Therapy.
2014
Conference Paper
GET IT
Times cited: 56 -
IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.
Leukemia.
2014
Academic Article
GET IT
Times cited: 121 -
Acute myeloid leukemia arising from a donor derived premalignant hematopoietic clone: A possible mechanism for the origin of leukemia in donor cells.
Leukemia research reports.
2014
Academic Article
GET IT
Times cited: 17 -
CD28z CARs and armored CARs.
Cancer journal (Sudbury, Mass.).
2014
Information Resource
GET IT
Times cited: 80 -
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Science translational medicine.
2014
Academic Article
GET IT
Times cited: 2067 -
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.
International journal of hematology.
2013
Information Resource
GET IT
Times cited: 91 -
CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models.
Biochemical and biophysical research communications.
2013
Academic Article
GET IT
Times cited: 18 -
The basic principles of chimeric antigen receptor design.
Cancer discovery.
2013
Information Resource
GET IT
Times cited: 1112 -
Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?.
Hematology/oncology clinics of North America.
2013
Review
GET IT
Times cited: 13 -
Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy.
Stem cells and development.
2013
Academic Article
GET IT
Times cited: 23 -
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.
Science translational medicine.
2013
Academic Article
GET IT
Times cited: 1710 -
In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice.
PloS one.
2012
Academic Article
GET IT
Times cited: 38 - How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology. 2012 Academic Article GET IT
-
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.
The journal of gene medicine.
2012
Information Resource
GET IT
Times cited: 201 -
CARs and cancers: questions and answers.
Blood.
2012
Comment
GET IT
Times cited: 12 -
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.
Blood.
2012
Academic Article
GET IT
Times cited: 569 -
Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.
Hematology. American Society of Hematology. Education Program.
2012
Information Resource
GET IT
Times cited: 72 -
Cellular therapies in acute lymphoblastic leukemia.
Hematology/oncology clinics of North America.
2011
Information Resource
GET IT
Times cited: 12 -
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.
Blood.
2011
Academic Article
GET IT
Times cited: 1119 -
In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy.
Cancer research.
2011
Academic Article
GET IT
Times cited: 84 -
CARs on track in the clinic.
Molecular therapy : the journal of the American Society of Gene Therapy.
2011
Conference Paper
GET IT
Times cited: 108 -
Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2010
Academic Article
GET IT
Times cited: 133 -
Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo.
Blood.
2010
Academic Article
GET IT
Times cited: 37 -
Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells.
Discovery medicine.
2010
Academic Article
GET IT
Times cited: 53 -
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.
Molecular therapy : the journal of the American Society of Gene Therapy.
2010
Letter
GET IT
Times cited: 342 -
Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer.
Discovery medicine.
2010
Review
GET IT
Times cited: 20 -
Cellular therapies in acute lymphoblastic leukemia.
Current opinion in molecular therapeutics.
2009
Review
GET IT
Times cited: 8 -
The promise and potential pitfalls of chimeric antigen receptors.
Current opinion in immunology.
2009
Information Resource
GET IT
Times cited: 400 -
Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase.
Nature medicine.
2009
Academic Article
GET IT
Times cited: 109 -
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997).
2009
Academic Article
GET IT
Times cited: 253 -
Retroviral transduction of murine primary T lymphocytes.
Methods in molecular biology (Clifton, N.J.).
2009
Academic Article
GET IT
Times cited: 36 -
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2008
Academic Article
GET IT
Times cited: 63 -
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.
Nature biotechnology.
2008
Academic Article
GET IT
Times cited: 104 -
Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application.
Human gene therapy.
2007
Academic Article
GET IT
Times cited: 30 -
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection.
Nature medicine.
2007
Academic Article
GET IT
Times cited: 208 -
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2007
Academic Article
GET IT
Times cited: 306 -
Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2007
Academic Article
GET IT
Times cited: 372 - Novel approaches to the immunotherapy of B-cell malignancies: An update. Current hematologic malignancy reports. 2006 Review GET IT
-
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2006
Academic Article
GET IT
Times cited: 140 -
Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
Cancer research.
2005
Academic Article
GET IT
Times cited: 94 -
Novel approaches to immunotherapy for B-cell malignancies.
Current hematology reports.
2005
Review
GET IT
Times cited: 6 -
Novel approaches to immunotherapy for B-cell malignancies.
Current oncology reports.
2004
Review
GET IT
Times cited: 4 -
Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes.
Current hematology reports.
2004
Information Resource
GET IT
Times cited: 17 -
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.
Nature medicine.
2003
Academic Article
GET IT
Times cited: 468 -
Targeting tumours with genetically enhanced T lymphocytes.
Nature reviews. Cancer.
2003
Information Resource
GET IT
Times cited: 365 -
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.
Nature biotechnology.
2002
Academic Article
GET IT
Times cited: 592 -
Fine tangled pili expressed by Haemophilus ducreyi are a novel class of pili.
Journal of bacteriology.
1996
Academic Article
GET IT
Times cited: 67 -
Haemophilus ducreyi adheres to human keratinocytes.
Microbial pathogenesis.
1994
Academic Article
GET IT
Times cited: 25